Merak Capital has led a $1.65 million investment round in Hakeem Health, a Saudi healthcare technology company building AI-powered clinical decision support tools. The round also included Sanabil 500 and is aimed at supporting the company’s expansion across healthcare institutions in the GCC. The announcement highlights growing investor interest in AI applications that can improve clinical efficiency, reduce errors, and support better patient outcomes.
AI-Driven Clinical Support
Hakeem Health’s main product, HakeemDx, is designed to assist clinicians with real-time, evidence-based medical insights at the point of care. The platform connects with hospital systems such as electronic medical records and laboratory platforms, allowing doctors and care teams to access guidance within existing workflows. Its bilingual Arabic and English capabilities are intended to address the needs of regional healthcare environments where multilingual clinical support is increasingly important.
The company operates through a software-as-a-service model and is targeting hospitals, universities, and healthcare payers through recurring institutional contracts. Hakeem Health sees a significant opportunity in regional markets, particularly Saudi Arabia, the UAE, and Egypt, where demand for digital healthcare infrastructure continues to grow. With more than 2,000 hospitals across these markets, the company is positioning HakeemDx as a scalable tool for broader adoption.
Investment Rationale
For Merak Capital, the investment fits within its broader focus on high-growth technology companies and the role of artificial intelligence in transforming major industries. The firm has emphasized AI as a driver of productivity and innovation, with healthcare viewed as one of the sectors where the technology can have a direct and measurable impact. The deal also aligns with Saudi Arabia’s Vision 2030 priorities, particularly digital transformation and the development of knowledge-based industries.
Merak Capital said Hakeem Health addresses practical challenges in clinical decision-making by helping medical professionals reach faster and more accurate assessments. The investment firm also pointed to the company’s experienced team and the potential for its technology to improve care delivery across regional health systems. Rather than replacing clinicians, the platform is positioned as a decision-support layer that strengthens medical judgment and workflow efficiency.
Regional Growth Plans
Hakeem Health plans to use the new funding to expand HakeemDx across hospitals and health systems in the GCC. Founder and CEO Bilal Adi described the company’s mission as helping clinicians make better decisions more quickly so that patients receive improved care. The backing from Merak Capital is expected to support product development, institutional partnerships, and broader deployment of trusted AI tools for clinical environments.
The company’s focus on local healthcare realities may prove important as Gulf health systems continue to modernize and digitize. By building a platform that supports Arabic and English and integrates with existing hospital infrastructure, Hakeem Health is targeting one of the major barriers to adoption in medical technology. Its approach reflects a wider regional trend toward AI solutions that are tailored to local regulatory, operational, and language requirements.
About the Investors and Company
Merak Capital is a Saudi-based multi-strategy investment firm licensed by the Capital Market Authority. The firm manages more than SAR 3 billion across 10 funds covering venture capital, private equity, credit financing, and special projects. Its investment approach focuses on companies with strong technology foundations, market growth potential, and alignment with emerging digital adoption cycles.
Hakeem Health is based in Saudi Arabia and is focused on making AI-first clinical decision support a standard part of care delivery across the GCC. Its flagship platform is built for use by regional health systems, including hospitals and public health authorities. The company is backed by regional investors seeking to support healthcare technology businesses that can scale from the Middle East to international markets.
The $1.65 million round gives Hakeem Health fresh momentum as healthcare providers across the region examine how AI can improve care quality and operational efficiency. For Merak Capital, the investment reflects confidence in applied AI companies that solve sector-specific problems and can scale across institutional markets. As HakeemDx expands, its progress will be watched as part of the wider shift toward AI-enabled healthcare in the GCC.